RT Journal Article SR Electronic T1 Primary drug resistance of mycobacterium tuberculosis in HIV-positive patients JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP PA2762 DO 10.1183/13993003.congress-2016.PA2762 VO 48 IS suppl 60 A1 Vasily Bondarenko A1 Irina Buynevich A1 Andrey Holyavkin A1 Svetlana Goponyako A1 Nkolaj Burinsky YR 2016 UL http://erj.ersjournals.com/content/48/suppl_60/PA2762.abstract AB Primary drug resistance (PDR) of Mycobacterium tuberculosis is detected in more than 34,5% new cases in Belarus and the portion increases annually. Gomel region has the highest level of HIV associated tuberculosis (TB) in Belarus (about 5,4% of new cases).The aim of study was to investigate PDR incidence and spectrum in HIV-positive patients in comparison with HIV-negative ones.We investigated 100 HIV-positive and 133 HIV-negative new TB cases. The groups were statistically equal by gender and age.PDR was detected by MBT cultivation on Loewenstein-Jensen medium.The results of study are represented in the table:DR spectrumHIV-positiveHIV-negativeReliable differencePDR70,0%54,1%No (p>0,05)Mono PDR13,3%10,5%No (p>0,05)Multiple PDR (isoniazid+ rifampicin)56,5%43,6%No (p>0,05)Summary PDR for isoniazid+ rifampicin+streptomycin57,4%51,4%No (p>0,05)Extensive PDR (isoniazid+ rifampicin+fluoroquinolones+at least one of three injectable second-line drugs (amikacin, capreomycin or kanamycin)1,6%2,0%No (p>0,05)The results of studyNeither PDR proportion no PDR spectrum reliable difference was found in groups of HIV-positive and HIV-negative patients.HIV-positivity was not concluded to be a reliable risk factor of PDR occurrence and didn't influence PDR spectrum.